UNSPSC 51132229: Aspirin/butalbital/caffeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132229 Aspirin/butalbital/caffeine (Commodity) covers pharmaceutical products state and local governments procure for emergency response, community health, and employee benefit programs — though recent activity under this code shows minimal direct solicitation for aspirin-based formulations and instead reflects broader pharmaceutical procurement across generic multi-source drugs and opioid-reversal agents. The actual buying pattern targets naloxone, generic pharmaceuticals distributed through state cooperative purchasing programs, and direct-to-manufacturer prescription fulfillment models rather than specific branded or combination analgesics. State and local issuing bodies soliciting under the code include county health departments (Seminole County, Florida), state HHS agencies running pharmacy benefit and therapeutic initiatives (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration's Office of State Procurement for MMCAP). The mix reflects both direct county-level purchasing for emergency-response inventories and state-aggregated procurement serving multiple participating jurisdictions.

Geographic concentration appears in Florida, Texas, and Minnesota, with MMCAP's multistate cooperative extending coverage to Oregon and other participating states. Recent representative opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capability information for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with awarded vendors effective July 1, 2026 and submission requirements including NDC codes, cGMP compliance certification, and pricing through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson.